Tactile Systems Technology Inc

Tactile Systems Technology Inc maintains a strong liquidity position, with a current ratio of 4.03 and $83.45 million in cash and equivalents, representing 30.5% of total assets. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure. Free cash flow of $23.20 million supports operational flexibility and potential reinvestment. Profitability metrics show a return on equity (ROE) of 8.72% and a return on assets (ROA) of 6.97%, both above the industry median for medical equipment firms. Gross margin of 50.8% (calculated from gross profit of $167.37 million on revenue of $329.52 million) is strong, though operating margin of 8.9% (operating income of $29.28 million) suggests room for improvement in cost control. The company operates in a single business segment focused on wound care, with all revenue derived from the sale of its Tactile Wound Care System. Geographic exposure is not disclosed in the provided data, but the company is headquartered in the United States and primarily serves the North American market. Outlook for the current fiscal year indicates stable revenue growth, with no significant changes in the product portfolio or market dynamics expected. The company's price-to-earnings ratio of 30.55 and price-to-book ratio of 2.66 suggest a premium valuation relative to book value, but align with industry norms for high-growth medical device firms. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued additional shares in the past year, and both basic and diluted shares outstanding remain unchanged at 22.75 million. No dilution pressure is currently evident. Recent events include a strong analyst outlook, with a mean price target of $38.00 and a median of $39.00, suggesting confidence in the company's growth trajectory. The mean recommendation of 1.80 (on a 1-5 scale) reflects a generally positive sentiment among analysts.